CYP2D6 POLYMORPHISMS AND ADVERSE EVENTS TO RISPERIDONE IN CHILDREN AND ADOLESCENTS.

被引：0
|
作者：
Neely, K. M. [1 ]
Oshikoya, K. A. [1 ]
Carroll, R. [1 ]
Aka, I. [1 ]
Maxwell-Horn, A. [1 ]
Roden, D. M. [1 ]
Van Driest, S. L. [1 ]
机构：
[1] Vanderbilt Univ, Med Ctr, 221 Kirkland Hall, Nashville, TN 37235 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2019年 / 105卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PGRN-027
引用
收藏
页码：S22 / S23
页数：2
相关论文
共 50 条
  • [41] Curbing Adverse Effects of CYP2D6 Substrates
    不详
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 112 (05) : 933 - 933
  • [42] CYP2D6 expression is regulated by polymorphisms that affect splicing and trancription: new biomarkers for CYP2D6 activity
    Wang, Danxin
    Poi, Ming J.
    Sun, Xiaochun
    Gaedigk, Andrea
    Leeder, J. Steven
    Sadee, Wolfgang
    FASEB JOURNAL, 2013, 27
  • [43] CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD
    Trzepacz, Paula T.
    Williams, David W.
    Feldman, Peter D.
    Wrishko, Rebecca E.
    Witcher, Jennifer W.
    Buitelaar, Jan K.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 (02) : 79 - 86
  • [44] CYP2D6 METABOLIZER PHENOTYPE PREDICTS ARIPIPRAZOLE PHARMACOKINETICS IN CHILDREN AND ADOLESCENTS
    Hiken, Eliah J.
    Poweleit, Ethan A.
    Keane, Corey
    Desta, Zeruesenay
    Strawn, Jeffrey R.
    Ramsey, Laura B.
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2023, 62 (10): : S197 - S197
  • [45] CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD
    Trzepacz, Paula T.
    Williams, David W.
    Feldman, Peter D.
    Witcher, Jennifer W.
    Buitelaar, Jan K.
    JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES, 2007, 19 (02) : 222 - 223
  • [46] CYP2D6 genotype and risperidone pharmacokinetics, pharmacodynamics and side effects
    Novalbos, J.
    Lopez-Rodriguez, R.
    Roman, M.
    PHARMACOGENOMICS, 2011, 12 (03) : 312 - 312
  • [47] IN VITRO COMPARATIVE INHIBITORY PROFILES OF SEVERAL CYP2D6 INHIBITORS AND METABOLIC CAPABILITIES OF CYP2D6*1, CYP2D6*2, CYP2D6*10, AND CYP2D6*17 ON TRAMADOL METABOLISM
    Nahid, N.
    Kanumuri, S.
    Sharma, A.
    Wang, D.
    Johnson, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S74 - S75
  • [48] Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension
    Zineh, I
    Beitelshees, AL
    Gaedigk, A
    Walker, JR
    Pauly, DF
    Eberst, K
    Leeder, JS
    Phillips, MS
    Gelfand, CA
    Johnson, JA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 76 (06) : 536 - 544
  • [49] CYP2D6 poor metabolisers: increased risk of metoprolol-associated adverse events
    Reactions Weekly, 2002, 932 (1) : 5 - 5
  • [50] Adverse drug interaction between risperidone and carbamazepine in a patient with chronic schizophrenia and deficient CYP2D6 activity
    Spina, E
    Scordo, MG
    Avenoso, A
    Perucca, E
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2001, 21 (01) : 108 - 109
12345